The AstraZeneca vaccineagainst coronavirus presents efficiency 74% in the prevention of Covid-19 disease with any symptoms, a rate that rises to 83.5% for those over 65, as shown by the results of its large clinical trial in the US.
The efficiency of 74% is slightly lower than the 79% that the company had announced in a preliminary stage in March and had later revised down to 76%. The new rate is based on the results of a double “blind” phase 3 vaccine in 32,451 volunteers from the US, Chile and Peru, of whom 21,635 received two doses of the vaccine and the rest placebo for comparison.
According toThe announcement was made in the American medical journal “New England Journal of Medicine”, according to Reuters, there were no serious or life-threatening cases of Covid-19 among the vaccinated, nor any deaths. Its effectiveness in preventing coronavirus infection (not symptomatic disease) was estimated at 64.3%, meaning that almost two out of three people who are vaccinated are not even infected with the virus.
“A pleasant surprise,” said Dr. Ana Derbin, according to the Athens News Agency, a vaccine specialist at Johns Hopkins University in Baltimore, who noted that the vaccine was “highly protective against serious illness and disease.” Also, there have been no cases of the rare side effect of thrombosis.
Following these findings, it remains to be seen what the fate of the vaccine will be in the US, where it has not yet even received approval for emergency release. The company has not ruled out the possibility of asking the American this year Food and Drug Administration (FDA) to issue direct normal – rather than urgent – authorization for its vaccine. A move that will be made more for prestige, rather than because the company hopes it will be used particularly in the US, where domestic mRNA vaccines (Moderna and Pfizer) have long dominated. The AstraZeneca vaccine, known as Vaxzevria, has already been approved and marketed in more than 170 countries.